Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9957135 | International Journal of Cardiology | 2005 | 5 Pages |
Abstract
The administration of 80 mg valsartan after bare metal stent implantation leads to a reduction of in-stent-restenosis compared to ACE-i. This effect is mainly due to beneficial effects of valsartan in cases with initial ACS. Major differences between ACE-i and valsartan are discussed including inflammation, activation of neutrophils, mode of bradykinin activation, AT2 receptor stimulation and apoptosis of smooth muscle cells.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Stefan Peters, Martina Trümmel, W. Meyners, B. Koehler, K. Westermann,